Adding tumor-bed biopsy to trimodality imaging after neoadjuvant chemotherapy did not reliably predict pathological complete ...

Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...

Most of the children who received medical care for EV-D68 from 2017 through 2022 -- 75% of those seen in the emergency ...

Today, companies across sectors including Swiggy, Dr Reddy’s Laboratories, Manappuram Finance, Reliance Power, Relaxo ...

In this season of pomp and circumstance celebrating graduates from preschool and beyond, it’s never too late in life to ...

Union Bank of India posted a 50.57% YoY rise in Q4FY25 net profit to Rs 4,984 crore, supported by strong non-interest income; ...

T-DXd plus THP led to significant improvements in pathologic complete response in patients with early-stage, HER2+ breast ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

QIAGEN N.V.’s (QGEN - Free Report) first-quarter 2025 adjusted earnings per share (EPS) were 55 cents, and 56 cents at ...

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...

Canara Bank's Q4 net profit rose 33% YoY to Rs 5,004 crore as other income offset pressure on margins; FY25 profit grew 17% ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...